- In December 2024, Sanofi presented new data at the American Society of Hematology (ASH) Annual Meeting, highlighting their commitment to innovation in rare blood diseases and cancers, including hemophilia and HLH. These presentations underscore Sanofi's ongoing efforts to advance treatment options in the HLH space
- In December 2024, Sobi announced new data at the ASH Annual Meeting, focusing on real-world treatment patterns and outcomes among patients with primary HLH. This data presentation emphasizes Sobi's dedication to improving treatment strategies and outcomes for HLH patients
- In January 2025, AB2 Bio Ltd. entered into a U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa, a potential treatment for primary monogenic IL-18 driven HLH. This agreement includes early payments and potential milestone payments, reflecting the strategic collaboration to bring this novel therapy to market
- In January 2025, Teva announced the launch of Copaxone (glatiramer acetate injection) for the treatment of secondary HLH in patients with multiple sclerosis. This launch represents Teva's expansion into the HLH treatment market, offering a new therapeutic option for patients with this rare condition
